The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

HOVON 143: ixazomib, daratumumab & low-dose dexamethasone for unfit & frail patients with NDMM

Dec 13, 2019

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Sonja Zweegman, Amsterdam UMC – VU University, Amsterdam, NL, discusses the HOVON 143 study: ixazomib, daratumumab & low-dose dexamethasone for unfit & frail patients with NDMM.

Sonja Zweegman talks about the results of the HOVON 143 trial, that focused on unfit & frail patients. She discusses the survival and response rate of patients that were treated with ixazomib, daratumumab & low-dose dexamethasone combination.

HOVON 143: ixazomib, daratumumab & low-dose dexamethasone for unfit & frail patients with NDMM